HK Stock Market Move | QYUNS-B (02509) surged by over 7%, acquiring Saifushi to enhance internal synergy and accelerate the approval process for core products such as QX002N.

QYUNS-B (02509) rose by over 7%, reaching 4.8% at the time of publication, at 14.86 Hong Kong dollars, with a turnover of 2.1053 million Hong Kong dollars. In terms of news, recently, QYUNS-B announced that Saifu Jilu (a wholly-owned subsidiary of the company) has entered into a stock transfer agreement with Taizhou Huacheng. Saifu Jilu conditionally agreed to acquire the target shares, while Taizhou Huacheng conditionally agreed to sell the target shares (approximately 34.0001% of the shares of Saifu Shishu). The acquisition is aimed at facilitating the smooth submission and approval of the new drug market applications (NDA) for the group's core pipeline products, Rusigkeit single infliximab (QX002N, anti-IL-17A monoclonal antibody) and Otto Kiba infliximab (QX005N, anti-IL-4R monoclonal antibody). The board of directors believes that the acquisition is in line with the overall business development strategy of the group, and believes that it will be beneficial to the overall management of the group's business. Furthermore, the target shares are state-owned assets, and the transfer of the target shares has been approved by the state asset supervision department and conducted through public listing. Additionally, after the completion of the acquisition, the company's stake in Saifu Shishu will increase from approximately 65.9999% to 100%. The directors believe that the acquisition is strategically aligned with the group's objectives of accelerating the approval of core products, enhancing synergy, and improving operational and management efficiency.